A Phase 4 interventional study of Cyclosporine 0.05% Ophthalmic Emulsion in Dry Eye Syndromes, sponsored by Allergan. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-06-01.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 21st largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2015, is one of 23 in phase 4, and was the 18th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
Ocular Aesthetics, LLC dba Ocular Clinical Trials · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+
The University of New South Wales · Sites in Australia
Ages 18+
Canyon City Eyecare · Sites in United States
Ages 18+
Baylor College of Medicine
Ages 18+
By country, each count listing its studies:
Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 51 across the 41 interventional studies. Of the 35 that completed or were terminated, 11 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
48 studies in Dry Eye Syndromes by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 47 finished, 40 (85%) have results posted.
Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 26th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2015, is one of 9 in phase 4, and was the 33rd registered.
AbbVie’s Dry Eye Syndromes studies by the year they started, since 2001.
5 of the studies testing cyclosporine in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06898853The University of New South WalesThe Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes | 2026-12-30 |
| NCT07553455Canyon City EyecareVevye + Flarex Combination Therapy for Dry Eye | 2026-12-31 |
| NCT07224529University of Alabama at BirminghamEfficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction | 2027-02-01 |
| NCT07904728Ocular Aesthetics, LLC dba Ocular Clinical TrialsTreating Contact Lens Discomfort With Cyclosporine 0.1% Ophthalmic Solution | 2027-03-15 |
| NCT07368595Baylor College of MedicineComparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, from their registry updates:
Among AbbVie’s 48 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy of Restasis® in participants with dry eye disease who engage in electronic visual tasking.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
1 drop of RESTASIS® ophthalmic emulsion instilled in each eye twice a day for 6 months.
Drug: Cyclosporine 0.05% Ophthalmic Emulsion
Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
Also known as: RESTASIS®
Change From Baseline in the Total Corneal Staining Score With Fluorescein in the Worse Eye
Total corneal staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
Time frame: Baseline, Month 6
Change From Baseline in the Total Conjunctival Staining Score With Fluorescein in the Worse Eye
Total conjunctival staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
Time frame: Baseline, Month 6
Change From Baseline in the Central Region Staining Score With Fluorescein in the Worse Eye
Staining with fluorescein in the central region of the eye was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
Time frame: Baseline, Month 6
Change From Baseline in the Total Corneal Staining Score With Lissamine Green in the Worse Eye
Total corneal staining with lissamine green was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
Time frame: Baseline, Month 6
Change From Baseline in the Total Conjunctival Staining Score With Lissamine Green in the Worse Eye
Total conjunctival staining with lissamine green was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
Time frame: Baseline, Month 6
Change From Baseline in the Central Region Staining Score With Lissamine Green in the Worse Eye
Staining with lissamine green in the central region of the eye was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
Time frame: Baseline, Month 6
Change From Baseline in Font Size
The minimum font (letter) size read correctly was assessed. Smaller font size (less points) indicates better ability. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening.
Time frame: Baseline, Month 6
Change From Baseline in Words Read Incorrectly
The numbers of words read incorrectly are counted. A positive change from Baseline indicates a worsening (more words read incorrectly) and a negative change from Baseline indicates an improvement.
Time frame: Baseline, Month 6
Change From Baseline in Time to Read Passage
The time to read passage (selected portion of text ) in seconds was assessed. A negative change from Baseline indicates an improvement (less time to read the passage).
Time frame: Baseline, Month 6
Change From Baseline in Reading Rate
Reading speed was assessed as the number of words read correctly calculated as words/minute. A positive change from Baseline indicates an improvement (more words read correctly/minute) and a negative change from Baseline indicates a worsening (less words read correctly/minute).
Time frame: Baseline, Month 6
Change From Baseline in Tear Film Break Up Time (TFBUT) in the Worse Eye
TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. The worse eye is defined as the Worse Eye at Baseline. A positive number change from Baseline indicates improvement and a negative number change from Baseline indicates a worsening.
Time frame: Baseline, Month 6
Change From Baseline in Ocular Protection Index (OPI) 2.0 in the Worse Eye
A device was used to assess OPI 2.0. This technology measures blink and tear film break-up area. These values demonstrate the average area of tear deficiency/corneal exposure. The worse eye is defined as the worse eye at Baseline. A negative value indicates an improvement in corneal protection.
Time frame: Baseline, Month 6
Change From Baseline in Interblink Interval (IBI) in the Worst Eye
A device was used to assess IBI. The IBI measures the time in seconds between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.
Time frame: Baseline, Month 6
Change From Baseline in OSDI© Total Score
The OSDI© questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions was assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0 to 100 point score where 0 is no symptoms and 100 is most symptoms. A negative change from Baseline indicates improvement.
Time frame: Baseline, Month 6
Change From Baseline in Driving at Night on the OSDI©
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Driving at Night question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in Working With a Computer or Bank Machine on the OSDI©
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Working with a Computer or Bank Machine question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in Watching Television (TV) on the OSDI©
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Watching TV question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in Blurred Vision on the OSDI©
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Blurred Vision question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in Poor Vision on the OSDI©
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Poor Vision question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in Reading on the OSDI©
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Reading question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
Time frame: Baseline, Month 6
Change From Baseline in the Ocular Discomfort Scale Post Wilkins Test in the Worst Eye
Participants assessed ocular discomfort post Wilkins Rate of Reading Test using the Ora Calibra™ 5-point scale where 0=no discomfort to 4=constant discomfort. A positive number change from Baseline indicates a worsening and a negative number change from Baseline indicates an improvement.
Time frame: Baseline, Month 6
| Milestone | RESTASIS® |
|---|---|
| Started | 51 |
| Completed | 46 |
| Not completed | 5 |
| Withdrew: Adverse event | 1 |
| Withdrew: Administrative reasons | 1 |
| Withdrew: Other miscellaneous reasons | 3 |
Total corneal staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 7.05 ± 1.011 |
| Change from Baseline at Month 6 | -1.51 ± 1.466 |
Total conjunctival staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 4.57 ± 1.237 |
| Change from Baseline at Month 6 | -0.61 ± 1.238 |
Staining with fluorescein in the central region of the eye was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 2.29 ± 0.441 |
| Change from Baseline at Month 6 | -0.75 ± 0.656 |
Total corneal staining with lissamine green was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 4.00 ± 1.378 |
| Change from Baseline at Month 6 | -0.34 ± 1.418 |
Total conjunctival staining with lissamine green was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 3.99 ± 1.486 |
| Change from Baseline at Month 6 | -0.18 ± 1.235 |
Staining with lissamine green in the central region of the eye was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 0.85 ± 0.822 |
| Change from Baseline at Month 6 | -0.24 ± 0.524 |
The minimum font (letter) size read correctly was assessed. Smaller font size (less points) indicates better ability. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening.
| points | RESTASIS® |
|---|---|
| Baseline | 9.0 ± 0.00 |
| Change from Baseline at Month 6 | 0.0 ± 0.21 |
The numbers of words read incorrectly are counted. A positive change from Baseline indicates a worsening (more words read incorrectly) and a negative change from Baseline indicates an improvement.
| incorrect words | RESTASIS® |
|---|---|
| Baseline | 16.6 ± 22.00 |
| Change from Baseline at Month 6 | -4.1 ± 16.64 |
The time to read passage (selected portion of text ) in seconds was assessed. A negative change from Baseline indicates an improvement (less time to read the passage).
| seconds | RESTASIS® |
|---|---|
| Baseline | 126.0 ± 28.64 |
| Change from Baseline at Month 6 | -0.7 ± 24.48 |
Reading speed was assessed as the number of words read correctly calculated as words/minute. A positive change from Baseline indicates an improvement (more words read correctly/minute) and a negative change from Baseline indicates a worsening (less words read correctly/minute).
| correct words/minute | RESTASIS® |
|---|---|
| Baseline | 146.6 ± 64.18 |
| Change from Baseline at Month 6 | -3.6 ± 69.80 |
TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. The worse eye is defined as the Worse Eye at Baseline. A positive number change from Baseline indicates improvement and a negative number change from Baseline indicates a worsening.
| seconds | RESTASIS® |
|---|---|
| Baseline | 2.38 ± 1.073 |
| Change from Baseline at Month 6 | -0.31 ± 1.258 |
A device was used to assess OPI 2.0. This technology measures blink and tear film break-up area. These values demonstrate the average area of tear deficiency/corneal exposure. The worse eye is defined as the worse eye at Baseline. A negative value indicates an improvement in corneal protection.
| percent of area | RESTASIS® |
|---|---|
| Baseline | 1.38 ± 2.064 |
| Change from Baseline at Month 6 | -0.87 ± 1.975 |
A device was used to assess IBI. The IBI measures the time in seconds between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement.
| seconds | RESTASIS® |
|---|---|
| Baseline | 5.27 ± 6.052 |
| Change from Baseline at Month 6 | -1.16 ± 6.399 |
The OSDI© questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions was assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0 to 100 point score where 0 is no symptoms and 100 is most symptoms. A negative change from Baseline indicates improvement.
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 45.1 ± 17.76 |
| Change from Baseline at Month 6 | -14.9 ± 16.50 |
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Driving at Night question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 1.7 ± 1.30 |
| Change from Baseline at Month 6 | -0.5 ± 1.14 |
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Working with a Computer or Bank Machine question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 1.9 ± 1.03 |
| Change from Baseline at Month 6 | -0.8 ± 1.08 |
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Watching TV question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 1.8 ± 1.11 |
| Change from Baseline at Month 6 | -0.9 ± 1.12 |
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Blurred Vision question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 1.7 ± 1.18 |
| Change from Baseline at Month 6 | -0.6 ± 0.86 |
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Poor Vision question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 1.5 ± 1.23 |
| Change from Baseline at Month 6 | -0.5 ± 0.84 |
The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Reading question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening.
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 1.5 ± 1.25 |
| Change from Baseline at Month 6 | -0.3 ± 1.15 |
Participants assessed ocular discomfort post Wilkins Rate of Reading Test using the Ora Calibra™ 5-point scale where 0=no discomfort to 4=constant discomfort. A positive number change from Baseline indicates a worsening and a negative number change from Baseline indicates an improvement.
| score on a scale | RESTASIS® |
|---|---|
| Baseline | 3.08 ± 1.017 |
| Change from Baseline at Month 6 | -0.60 ± 1.232 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RESTASIS® | — | 3/50 (6%) | 6/50 (12%) |
| Event | RESTASIS® |
|---|---|
| Papillary thyroid carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/50 |
| Peripheral vascular diseaseVascular disorders | 1/50 |
| Carbon monoxide poisoningInjury, poisoning and procedural complications | 1/50 |
| Event | RESTASIS® |
|---|---|
| Visual acuity reducedEye disorders | 3/50 |
| NasopharyngitisInfections and infestations | 3/50 |
51 participants were initially enrolled in the study, 1 participant discontinued before dosing and is not included in the Intent-to-treat (ITT) population.
| Age, Continuous(years) | RESTASIS® |
|---|---|
| Mean | 46.3 ± 8.3 |
| Sex: Female, Male(Participants) | RESTASIS® |
|---|---|
| Female | 41 |
| Male | 9 |
Ran from Jul 2015 to primary completion in Mar 2016, 8 months.
Results were first posted in Jun 2017, 1 year 2 months after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 8 months is close to that.
Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine